Evidence map›Paper›PMID 41122516›Full record

ArticleFrontiers in medicine2025

Network pharmacology, molecular docking and

Xuejuan Zan, Shunying Zhang, Qikun Liu, Fang Wang, Maogui Tian, Yu Cao

Abstract read
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xuejuan ZanDepartment of Dermatology, Xingyi People's Hospital, Guizhou Medical University, Xingyi, Guizhou, China.
Shunying ZhangDepartment of Dermatology, Xingyi People's Hospital, Guizhou Medical University, Xingyi, Guizhou, China.
Qikun LiuDepartment of Dermatology, Xingyi People's Hospital, Guizhou Medical University, Xingyi, Guizhou, China.
Fang WangDepartment of Dermatology, Xingyi People's Hospital, Guizhou Medical University, Xingyi, Guizhou, China.
Maogui TianDepartment of Dermatology, Xingyi People's Hospital, Guizhou Medical University, Xingyi, Guizhou, China.
Yu CaoSchool of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Psoriasis remains incurable, driving the need for new treatments. This study evaluated the therapeutic effects of oleanolic acid on IMQ-induced psoriasis model mice and used network pharmacology and molecular docking to predict its mechanism of action. Methods: This study assessed the different concentrations (1%, 5%, 10%) of oleanolic acid cream effects on IMQ-induced psoriasis in female BALB/c mice, evaluating therapeutic outcomes via PASI scores, skin lesion staining, and inflammatory factor detection. Network pharmacology and molecular docking predicted OA's mechanism. Key targets were identified using databases and software analyses. Results: Oleanolic acid can treat skin damage in psoriasis model mice and improve systemic inflammatory responses. Network pharmacology results identified important potential targets for OA treatment of psoriasis, including HSP90AA1, STAT3, MAPK3, HSP90AB1, PPARG, PTGS2, AR, CDK1. GO functional enrichment analysis involved biological functions such as inflammation response, signal transduction, G protein-coupled receptor signaling pathway, etc. KEGG pathway enrichment analysis involved signaling pathways such as neuroactive ligand-receptor interaction, PPAR signaling pathway, Th17 cell differentiation, etc. Molecular docking results showed good affinity between oleanolic acid and MAPK3, STAT3, AR, PPARG. Conclusion: Oleanolic acid has therapeutic effects on psoriasis, with possible target points being MAPK3, STAT3, AR, and PPARG, involving processes such as inflammation response, negative regulation of cell proliferation, and Th17 cell differentiation.

Indexed as

BALB/c micemolecular dockingnetwork pharmacologyoleanolic acidpsoriasis

Identifiers

PMID41122516
PMCPMC12535998

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.